| Code | 8709D | ||||||||||
| MA number | 44/0257/21-S | ||||||||||
| Product Form: | tbl 120x250 mg (fľ.HDPE) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | G.L. Pharma GmbH, Austria | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | bottle HDPE | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 27.10.2021 |
| SPC: |
SPC_Abiraterone G.L. Pharma 250 mg tablety_10_2021.pdf
|
| PIL: |
PIL_Abiraterone G.L. Pharma 250 mg tablety_10_2021.pdf
|
| Safety feature | Yes |
| Data update: | 13.10.2025 |
